EMAGine SA
Medical device for ophthalmic treatment
CXL (corneal collagen-cross-linking) is a relatively new ophthalmic treatment that uses UV-light and riboflavin to create biochemical and biomechanical changes that strengthen a compromised or diseased cornea. Initially developped for the traitement of corneal degeneration (keratoconus), recent reports indicate that CXL is also effective in arresting all forms of corneal infections (more frequent than keratoconus). With these findings, Prof. Hafezi and Dr. Olivier Richoz are developing a medical device (C-EyeTip©) to be used for both keratoconus and corneal infection.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
Videos
Conventional cross-linking treatment (CXL) requiring an operating theatre
Human cornea: shift from normal to keratoconus
Cross-links in the human cornea
Documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
EMAGine SA
Medical device for ophthalmic treatment
Headquarter:
Zug
Foundation Date:
February 2013
Technology:
- Medtech
Sectors:
- Surgery
Support received
